Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- North Estonia Medical Centre
- Target Recruit Count
- 50
- Registration Number
- NCT06505369
- Locations
- 🇳🇴
Oslo University Hospital, Oslo Myeloma Centre, Oslo, Norway
🇳🇴Stavanger University Hospital, Stavanger, Norway
🇩🇰Vejle hospital, Vejle, Denmark
A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM (FUMANBA-03)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06464991
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing GoBoard Boren Hospital, Beijing, China
🇨🇳Fu Xing Hospital, Capital Medical University, Beijing, China
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 450
- Registration Number
- NCT06413498
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Clinica Universidad de Navarra, Pamplona, Spain
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Conditions
- T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06390319
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT06353022
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
🇫🇷CH de la Côte Basque, Bayonne, France
🇫🇷CHU Caen, Caen, France
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
- Conditions
- Newly Diagnosed Multiple MyelomaMultiple MyelomaAutologous Stem Cell Transplantation
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06348147
- Locations
- 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
- Conditions
- Systemic Amyloidosis
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Jin Lu, MD
- Target Recruit Count
- 40
- Registration Number
- NCT06342466
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Two Schemes Response in Multiple Myeloma
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Hospital General de Mexico
- Target Recruit Count
- 83
- Registration Number
- NCT06284395
- Locations
- 🇲🇽
Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City, Cdmx, Mexico
An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06215638
- Locations
- 🇨🇳
Peking Union Medical Cllege Hospital, Beijing, Beijing, China
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- 🇬🇷
251 Airforces Hospital, Athens, Greece
🇹🇷Ankara University Medical Faculty, Ankara, Turkey
🇹🇷Liv Hospital Ankara, Ankara, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.